BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Grasp Cancer - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Grasp Cancer
X-ORIGINAL-URL:https://graspcancer.org
X-WR-CALDESC:Events for Grasp Cancer
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Winnipeg
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20240310T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20241103T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20250309T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20251102T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20260308T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20261101T070000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251218T140000
DTEND;TZID=America/New_York:20251218T153000
DTSTAMP:20260502T102938
CREATED:20251125T183001Z
LAST-MODIFIED:20260409T151110Z
UID:10000223-1766066400-1766071800@graspcancer.org
SUMMARY:SABCS25 - Group 5E: HER2-negative Metastatic Breast Cancer; Brain Metastasis; Leptomeningeal Disease
DESCRIPTION:  \nThe 2025 San Antonio Breast Cancer Symposium (SABCS) is a global meeting that highlights clinical\, translational\, and basic breast cancer research. It’s a unique opportunity for advocates to join the conversation. \n\nRegister Below\nThis SABCS25 Poster Walkthrough group will explore key findings from the following posters: \nPoster #PS5-03-01: Phase I Study of Stereotactic Radiation and Sacituzumab Govitecan with Zimberelimab in the Management of Metastatic Triple Negative Breast Cancer with Brain Metastases \nPoster #PS1-09-02: Intracranial activity of datopotamab deruxtecan (Dato-DXd) for patients with HER2-negative breast cancer and leptomeningeal disease (LMD): Results from Cohort C of the DATO-BASE phase 2 trial
URL:https://graspcancer.org/event/sabcs25-group5e/
CATEGORIES:Poster Walkthrough
LOCATION:https://graspcancer.org/event/sabcs25-group5e/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251218T140000
DTEND;TZID=America/New_York:20251218T153000
DTSTAMP:20260502T102938
CREATED:20251125T182004Z
LAST-MODIFIED:20260409T151127Z
UID:10000222-1766066400-1766071800@graspcancer.org
SUMMARY:SABCS25 - Group 5D: HER2+ Locally Advanced and Metastatic Breast Cancer; Antibody-drug Conjugates; Treatment Resistance
DESCRIPTION:  \nThe 2025 San Antonio Breast Cancer Symposium (SABCS) is a global meeting that highlights clinical\, translational\, and basic breast cancer research. It’s a unique opportunity for advocates to join the conversation. \n\nRegister Below\nThis SABCS25 Poster Walkthrough group will explore key findings from the following posters: \nPoster #PS5-12-23: Real-world outcomes of patients with HER2+ metastatic breast cancer after treatment with trastuzumab deruxtecan (T-DXd) in the United States \nPoster #PS5‑01‑16: Phase II Trial of the FASN Inhibitor\, Denifanstat (TVB‑2640)\, Plus Trastuzumab in Combination with Paclitaxel or Endocrine Therapy in Patients with HER2+ MBC Resistant to Trastuzumab
URL:https://graspcancer.org/event/sabcs25-group5d/
CATEGORIES:Poster Walkthrough
LOCATION:https://graspcancer.org/event/sabcs25-group5d/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251218T140000
DTEND;TZID=America/New_York:20251218T153000
DTSTAMP:20260502T102938
CREATED:20251125T181004Z
LAST-MODIFIED:20260409T151140Z
UID:10000221-1766066400-1766071800@graspcancer.org
SUMMARY:SABCS25 - Group 5C: Metastatic Breast Cancer; Antibody-drug Conjugates; Treatment Response and Resistance
DESCRIPTION:  \nThe 2025 San Antonio Breast Cancer Symposium (SABCS) is a global meeting that highlights clinical\, translational\, and basic breast cancer research. It’s a unique opportunity for advocates to join the conversation. \nPrefer a different time? These same posters will be discussed in another session. Click to join Group 4C instead. \n\nRegister Below\nThis SABCS25 Poster Walkthrough group will explore key findings from the following posters: \nPoster #PS2-07-15: Immune biomarkers of standard-of-care chemoimmunotherapy response and resistance in real-world patient population: TBCRC061 \nPoster #PS4-02-23: Biomarkers of response and resistance to Sacituzumab Govitecan in HR+/HER2− advanced breast cancer: interim results from the phase II SOLTI ACROSS-TROP2 Trial
URL:https://graspcancer.org/event/sabcs25-group5c/
CATEGORIES:Poster Walkthrough
LOCATION:https://graspcancer.org/event/sabcs25-group5c/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251218T140000
DTEND;TZID=America/New_York:20251218T153000
DTSTAMP:20260502T102938
CREATED:20251125T180505Z
LAST-MODIFIED:20260409T151226Z
UID:10000220-1766066400-1766071800@graspcancer.org
SUMMARY:SABCS25 - Group 5B: Metastatic Breast Cancer; Symptom Management; Dosing Strategies
DESCRIPTION:  \nThe 2025 San Antonio Breast Cancer Symposium (SABCS) is a global meeting that highlights clinical\, translational\, and basic breast cancer research. It’s a unique opportunity for advocates to join the conversation. \nPrefer a different time? These same posters will be discussed in another session. Click to join Group 1F instead. \n\nRegister Below\nThis SABCS25 Poster Walkthrough group will explore key findings from the following posters: \nPoster #PS2-03-17: Dose reductions in metastatic breast cancer patients: Frequency\, strategies\, and patient experience \nPoster #PS1-08-13: A retrospective study to assess real world rates of dose modification\, therapy discontinuation and treatment outcomes in patients receiving the oral CDK4/6 inhibitors Ribociclib and Palbociclib. \n 
URL:https://graspcancer.org/event/sabcs25-group5b/
CATEGORIES:Poster Walkthrough
LOCATION:https://graspcancer.org/event/sabcs25-group5b/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251218T140000
DTEND;TZID=America/New_York:20251218T153000
DTSTAMP:20260502T102938
CREATED:20251125T180005Z
LAST-MODIFIED:20260409T151237Z
UID:10000192-1766066400-1766071800@graspcancer.org
SUMMARY:SABCS25 - Group 5A: Lobular Breast Cancer; Risk Prediction
DESCRIPTION:  \nThe 2025 San Antonio Breast Cancer Symposium (SABCS) is a global meeting that highlights clinical\, translational\, and basic breast cancer research. It’s a unique opportunity for advocates to join the conversation. \n\nRegister Below\nThis SABCS25 Poster Walkthrough group will explore key findings from the following posters: \nPoster #PS3-11-06: Long-term prognostic and predictive value of lobular histology in the PALLAS trial \nPoster #PS3-07-21: Validation of the CTS5 as a predictor of late distant recurrence (DR) for HR+ HER2-negative Invasive Lobular Carcinoma (ILC)
URL:https://graspcancer.org/event/sabcs25-group5a/
CATEGORIES:Poster Walkthrough
LOCATION:https://graspcancer.org/event/sabcs25-group5a/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251218T100000
DTEND;TZID=America/New_York:20251218T113000
DTSTAMP:20260502T102938
CREATED:20251125T162005Z
LAST-MODIFIED:20260409T150442Z
UID:10000219-1766052000-1766057400@graspcancer.org
SUMMARY:SABCS25 - Group 4E: HR+ Locally Advanced and Metastatic Breast Cancer; PIK3CA Mutations; Treatment Resistance
DESCRIPTION:  \nThe 2025 San Antonio Breast Cancer Symposium (SABCS) is a global meeting that highlights clinical\, translational\, and basic breast cancer research. It’s a unique opportunity for advocates to join the conversation. \nPrefer a different time? These same posters will be discussed in another session. Click to join Group 3D instead. \n\nRegister Below\nThis SABCS25 Poster Walkthrough group will explore key findings from the following posters: \nPoster #PS5-08-19: Randomized phase 3 trial evaluating KAT6 inhibitor PF-07248144 plus fulvestrant in HR+HER2− advanced/metastatic breast cancer after progression on CDK4/6 inhibitor-based therapy \nPoster #PS5-08-25: ReDiscover-2\, a phase 3 study of RLY-2608 + fulvestrant versus capivasertib + fulvestrant as treatment for locally advanced or metastatic PIK3CA-mutant HR+/ HER2- breast cancer following recurrence or progression on or after treatment with a CDK4/6 inhibitor (trial in progress)
URL:https://graspcancer.org/event/sabcs25-group4e/
CATEGORIES:Poster Walkthrough
LOCATION:https://graspcancer.org/event/sabcs25-group4e/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251218T100000
DTEND;TZID=America/New_York:20251218T113000
DTSTAMP:20260502T102938
CREATED:20251125T161506Z
LAST-MODIFIED:20260409T150451Z
UID:10000218-1766052000-1766057400@graspcancer.org
SUMMARY:SABCS25 - Group 4D: Triple Negative Locally Advanced and Metastatic Breast Cancer; Antibody-drug Conjugates; Immunotherapy
DESCRIPTION:  \nThe 2025 San Antonio Breast Cancer Symposium (SABCS) is a global meeting that highlights clinical\, translational\, and basic breast cancer research. It’s a unique opportunity for advocates to join the conversation. \n\nRegister Below\nThis SABCS25 Poster Walkthrough group will explore key findings from the following posters: \nPoster #PS5-02-28: Safety analysis of phase 3 ASCENT-04 study of sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro for previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC) \nPoster #PS5-08-18: Trofuse-011: a phase 3\, randomized\, open-label study of sacituzumab tirumotecan with or without pembrolizumab vs treatment of physician’s choice for previously untreated locally recurrent unresectable or metastatic triple-negative breast cancer
URL:https://graspcancer.org/event/sabcs25-group4d/
CATEGORIES:Poster Walkthrough
LOCATION:https://graspcancer.org/event/sabcs25-group4d/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251218T100000
DTEND;TZID=America/New_York:20251218T113000
DTSTAMP:20260502T102938
CREATED:20251125T160506Z
LAST-MODIFIED:20260409T150808Z
UID:10000215-1766052000-1766057400@graspcancer.org
SUMMARY:SABCS25 - Group 4B: Metastatic Breast Cancer; Bone Metastasis
DESCRIPTION:  \nThe 2025 San Antonio Breast Cancer Symposium (SABCS) is a global meeting that highlights clinical\, translational\, and basic breast cancer research. It’s a unique opportunity for advocates to join the conversation. \n\nRegister Below\nThis SABCS25 Poster Walkthrough group will explore key findings from the following posters: \nPoster #PS1-12-16: Chromatin Reader ZMYND8 Promotes Breast Cancer Bone Metastasis \nPoster #PS1-13-18: Single Intratumoral Drug Injection Yields Complete Response (CR) in Metastatic Breast Cancer (MBC) Bone Lesions: Results from a Phase 2a Trial
URL:https://graspcancer.org/event/sabcs25-group4b/
CATEGORIES:Poster Walkthrough
LOCATION:https://graspcancer.org/event/sabcs25-group4b/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251218T100000
DTEND;TZID=America/New_York:20251218T113000
DTSTAMP:20260502T102938
CREATED:20251125T160007Z
LAST-MODIFIED:20260409T150818Z
UID:10000191-1766052000-1766057400@graspcancer.org
SUMMARY:SABCS25 - Group 4A: HER2+ and HER2-low Metastatic Breast Cancer; Antibody-drug Conjugates; Treatment Resistance
DESCRIPTION:  \nThe 2025 San Antonio Breast Cancer Symposium (SABCS) is a global meeting that highlights clinical\, translational\, and basic breast cancer research. It’s a unique opportunity for advocates to join the conversation. \nPrefer a different time? These same posters will be discussed in another session. Click to join Group 3C instead. \n\nRegister Below\nThis SABCS25 Poster Walkthrough group will explore key findings from the following posters: \nPoster #PS3-04-16: Decoding resistance to trastuzumab deruxtecan in metastatic breast cancer: S100P signaling and immune-niche barriers \nPoster #PS5-01-24: Evorpacept (ALX-148) combined with trastuzumab deruxtecan in patients with HER2 positive/HER2low metastatic breast cancer (mBC): results from the PRE-ISPY phase Ib trial
URL:https://graspcancer.org/event/sabcs25-group4a/
CATEGORIES:Poster Walkthrough
LOCATION:https://graspcancer.org/event/sabcs25-group4a/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251217T180000
DTEND;TZID=America/New_York:20251217T193000
DTSTAMP:20260502T102938
CREATED:20251125T152008Z
LAST-MODIFIED:20260409T150308Z
UID:10000209-1765994400-1765999800@graspcancer.org
SUMMARY:SABCS25 - Group 3E: Metastatic Breast Cancer; Antibody-drug Conjugates; Treatment Resistance
DESCRIPTION:  \nThe 2025 San Antonio Breast Cancer Symposium (SABCS) is a global meeting that highlights clinical\, translational\, and basic breast cancer research. It’s a unique opportunity for advocates to join the conversation. \n\nRegister Below\nThis SABCS25 Poster Walkthrough group will explore key findings from the following posters: \nPoster #PS5-08-07: Open-label Single-arm Phase 2 Trial of Trastuzumab Deruxtecan in Previously Treated HER2-Immunohistochemistry (IHC) 0 Advanced Breast Cancer – HER2 PARADIGM trial \nPoster #PS5-05-20: Real-world treatment patterns and outcomes in patients with HER2+ metastatic breast cancer after treatment with trastuzumab deruxtecan (T-DXd) in the US
URL:https://graspcancer.org/event/sabcs25-group3e/
CATEGORIES:Poster Walkthrough
LOCATION:https://graspcancer.org/event/sabcs25-group3e/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251217T180000
DTEND;TZID=America/New_York:20251217T193000
DTSTAMP:20260502T102938
CREATED:20251125T151508Z
LAST-MODIFIED:20260409T150326Z
UID:10000208-1765994400-1765999800@graspcancer.org
SUMMARY:SABCS25 - Group 3D: HR+ Locally Advanced and Metastatic Breast Cancer; PIK3CA Mutations; Treatment Resistance
DESCRIPTION:  \nThe 2025 San Antonio Breast Cancer Symposium (SABCS) is a global meeting that highlights clinical\, translational\, and basic breast cancer research. It’s a unique opportunity for advocates to join the conversation. \nPrefer a different time? These same posters will be discussed in another session. Click to join Group 4E instead. \n\nRegister Below\nThis SABCS25 Poster Walkthrough group will explore key findings from the following posters: \nPoster #PS5-08-19: Randomized phase 3 trial evaluating KAT6 inhibitor PF-07248144 plus fulvestrant in HR+HER2− advanced/metastatic breast cancer after progression on CDK4/6 inhibitor-based therapy \nPoster #PS5-08-25: ReDiscover-2\, a phase 3 study of RLY-2608 + fulvestrant versus capivasertib + fulvestrant as treatment for locally advanced or metastatic PIK3CA-mutant HR+/ HER2- breast cancer following recurrence or progression on or after treatment with a CDK4/6 inhibitor (trial in progress)
URL:https://graspcancer.org/event/sabcs25-group3d/
CATEGORIES:Poster Walkthrough
LOCATION:https://graspcancer.org/event/sabcs25-group3d/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251217T180000
DTEND;TZID=America/New_York:20251217T193000
DTSTAMP:20260502T102938
CREATED:20251125T151009Z
LAST-MODIFIED:20260409T150340Z
UID:10000205-1765994400-1765999800@graspcancer.org
SUMMARY:SABCS25 - Group 3C: HER2+ and HER2-low Metastatic Breast Cancer; Antibody-drug Conjugates; Treatment Resistance
DESCRIPTION:  \nThe 2025 San Antonio Breast Cancer Symposium (SABCS) is a global meeting that highlights clinical\, translational\, and basic breast cancer research. It’s a unique opportunity for advocates to join the conversation. \nPrefer a different time? These same posters will be discussed in another session. Click to join Group 4A instead. \n\nRegister Below\nThis SABCS25 Poster Walkthrough group will explore key findings from the following posters: \nPoster #PS3-04-16: Decoding resistance to trastuzumab deruxtecan in metastatic breast cancer: S100P signaling and immune-niche barriers \nPoster #PS5-01-24: Evorpacept (ALX-148) combined with trastuzumab deruxtecan in patients with HER2 positive/HER2low metastatic breast cancer (mBC): results from the PRE-ISPY phase Ib trial
URL:https://graspcancer.org/event/sabcs25-group3c/
CATEGORIES:Poster Walkthrough
LOCATION:https://graspcancer.org/event/sabcs25-group3c/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251217T180000
DTEND;TZID=America/New_York:20251217T193000
DTSTAMP:20260502T102938
CREATED:20251125T150509Z
LAST-MODIFIED:20260409T150350Z
UID:10000225-1765994400-1765999800@graspcancer.org
SUMMARY:SABCS25 - Group 3B: Early Stage Breast Cancer; Liquid Biopsy
DESCRIPTION:  \nThe 2025 San Antonio Breast Cancer Symposium (SABCS) is a global meeting that highlights clinical\, translational\, and basic breast cancer research. It’s a unique opportunity for advocates to join the conversation. \n\nRegister Below\nThis SABCS25 Poster Walkthrough group will explore key findings from the following posters: \nPoster #PS2-09-18: Real-time liquid biopsy assessment in early-stage breast cancer: methylation based-ctDNA analysis and CTCs detection as potential predictors of response to neoadjuvant therapy \nPoster #PS2-09-20: Circulating Tumor DNA Dynamics and Anatomical Patterns of Relapse Following Curative Therapy in Early-Stage Breast Cancer
URL:https://graspcancer.org/event/sabcs25-group3b/
CATEGORIES:Poster Walkthrough
LOCATION:https://graspcancer.org/event/sabcs25-group3b/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251217T180000
DTEND;TZID=America/New_York:20251217T193000
DTSTAMP:20260502T102938
CREATED:20251125T150010Z
LAST-MODIFIED:20260409T150405Z
UID:10000190-1765994400-1765999800@graspcancer.org
SUMMARY:SABCS25 - Group 3A: BEGINNER TRACK: Metastatic Breast Cancer; Side Effects; Symptom Management
DESCRIPTION:  \nThe 2025 San Antonio Breast Cancer Symposium (SABCS) is a global meeting that highlights clinical\, translational\, and basic breast cancer research. It’s a unique opportunity for advocates to join the conversation. \nThese beginner tracks offer added explanations at a relaxed pace\, ideal for new advocates and anyone who prefers additional clarity. \n\nRegister Below\nThis SABCS25 Poster Walkthrough group will explore key findings from the following posters: \nPoster #PS1-04-15: A focused evaluation of young adults living with metastatic breast cancer: Patient-reported strategies to alleviate disease symptoms\, treatment-related side effects\, and survivorship concerns \nPoster #PS1-02-22: Delayed Palliative Care in Metastatic Breast Cancer: Rationale for Early Integration
URL:https://graspcancer.org/event/sabcs25-group3a/
CATEGORIES:Poster Walkthrough
LOCATION:https://graspcancer.org/event/sabcs25-group3a/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251217T140000
DTEND;TZID=America/New_York:20251217T153000
DTSTAMP:20260502T102938
CREATED:20251210T214558Z
LAST-MODIFIED:20260409T150005Z
UID:10000226-1765980000-1765985400@graspcancer.org
SUMMARY:SABCS25 - 🇧🇷 Group 2G: Saúde sexual na sobrevivência ao câncer; Retorno ao trabalho
DESCRIPTION:  \nSan Antonio Breast Cancer Symposium (SABCS)\, a maior conferência de pesquisa em câncer de mama do mundo\, se torna ainda mais especial com as discussões do GRASP\, que reúne pacientes e cientistas em pequenos grupos para conversar sobre os estudos apresentados na conferência. \nInscreva-se abaixo \nEste grupo do GRASP Poster Walkthrough vai explorar resultados essenciais dos seguintes pôsteres: \nPôster #PS1-01-25: Vamos falar sobre sexualidade no cuidado oncológico: uma análise transversal de um programa multicêntrico de sobrevivência \nPôster #PS1-01-28: Traçando o caminho de volta ao trabalho: uma análise transversal de um programa multicêntrico de sobrevivência
URL:https://graspcancer.org/event/sabcs25-group2g/
CATEGORIES:Poster Walkthrough
LOCATION:https://graspcancer.org/event/sabcs25-group2g/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251217T140000
DTEND;TZID=America/New_York:20251217T153000
DTSTAMP:20260502T102938
CREATED:20251125T142511Z
LAST-MODIFIED:20260409T150022Z
UID:10000204-1765980000-1765985400@graspcancer.org
SUMMARY:SABCS25 - Group 2E: Metastatic Breast Cancer; Brain Metastasis Risk Prediction
DESCRIPTION:  \nThe 2025 San Antonio Breast Cancer Symposium (SABCS) is a global meeting that highlights clinical\, translational\, and basic breast cancer research. It’s a unique opportunity for advocates to join the conversation. \nPrefer a different time? These same posters will be discussed in another session. Click to join Group 1C instead. \n\nRegister Below\nThis SABCS25 Poster Walkthrough group will explore key findings from the following posters: \nPoster #PS5-01-08: Development of the HER2DX Predictor of Brain Metastasis in Advanced HER2-Positive Breast Cancer Treated with First-Line THP \nPoster #PS2-08-05: Multimodal integration of real world genomic and clinical data for the prediction of brain metastasis development in breast cancer
URL:https://graspcancer.org/event/sabcs25-group2e/
CATEGORIES:Poster Walkthrough
LOCATION:https://graspcancer.org/event/sabcs25-group2e/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251217T140000
DTEND;TZID=America/New_York:20251217T153000
DTSTAMP:20260502T102938
CREATED:20251125T142011Z
LAST-MODIFIED:20260409T150042Z
UID:10000203-1765980000-1765985400@graspcancer.org
SUMMARY:SABCS25 - Group 2D: HR+ Metastatic Breast Cancer; ESR1 Mutations; Targeted Therapies; Treatment Resistance
DESCRIPTION:  \nThe 2025 San Antonio Breast Cancer Symposium (SABCS) is a global meeting that highlights clinical\, translational\, and basic breast cancer research. It’s a unique opportunity for advocates to join the conversation. \n\nRegister Below\nThis SABCS25 Poster Walkthrough group will explore key findings from the following posters: \nPoster #PS1-07-11: Vepdegestrant Overcomes Endocrine and CDK4/6i Resistance to Enhance Radiosensitivity in ESR1 mutant ER+ Breast Cancer \nPoster #PS2-02-04: Real-world treatment patterns and clinical outcomes in patients with emerging estrogen receptor 1 (ESR1)-mutated ER+ metastatic breast cancer in the U.S.\, 2018-2024
URL:https://graspcancer.org/event/sabcs25-group2d/
CATEGORIES:Poster Walkthrough
LOCATION:https://graspcancer.org/event/sabcs25-group2d/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251217T140000
DTEND;TZID=America/New_York:20251217T153000
DTSTAMP:20260502T102938
CREATED:20251125T141512Z
LAST-MODIFIED:20260409T150103Z
UID:10000202-1765980000-1765985400@graspcancer.org
SUMMARY:SABCS25 - Group 2C: HER2-negative Metastatic Breast Cancer; Tumor Immune Microenvironment
DESCRIPTION:  \nThe 2025 San Antonio Breast Cancer Symposium (SABCS) is a global meeting that highlights clinical\, translational\, and basic breast cancer research. It’s a unique opportunity for advocates to join the conversation. \n\nRegister Below\nThis SABCS25 Poster Walkthrough group will explore key findings from the following posters: \nPoster #PS3-12-27: Comparative analysis of the tumor immune microenvironment (TIME) and primary and metastatic tissue in HR+/HER2- and triple-negative breast cancer (TNBC) \nPoster #PS3-13-16: Cancer systems immunology unravels complexity of reversing immune suppression and predicts beyond RECIST in metastatic breast cancer
URL:https://graspcancer.org/event/sabcs25-group2c/
CATEGORIES:Poster Walkthrough
LOCATION:https://graspcancer.org/event/sabcs25-group2c/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251217T140000
DTEND;TZID=America/New_York:20251217T153000
DTSTAMP:20260502T102938
CREATED:20251125T140512Z
LAST-MODIFIED:20260409T150123Z
UID:10000201-1765980000-1765985400@graspcancer.org
SUMMARY:SABCS25 - Group 2B: Lobular Breast Cancer; Disease Monitoring; Liquid Biopsy
DESCRIPTION:  \nThe 2025 San Antonio Breast Cancer Symposium (SABCS) is a global meeting that highlights clinical\, translational\, and basic breast cancer research. It’s a unique opportunity for advocates to join the conversation. \n\nRegister Below\nThis SABCS25 Poster Walkthrough group will explore key findings from the following posters: \nPoster #PS2-09-04: Predicting outcomes for patients with mixed ductal/lobular carcinoma of the breast based on circulating tumor DNA positivity patterns \nPoster #PS2-07-22: Serial\, multi-omic\, multi-analyte\, liquid biopsy monitoring of metastatic lobular breast cancer to detect clinically-relevant heterogeneity and evolution
URL:https://graspcancer.org/event/sabcs25-group2b/
CATEGORIES:Poster Walkthrough
LOCATION:https://graspcancer.org/event/sabcs25-group2b/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251217T140000
DTEND;TZID=America/New_York:20251217T153000
DTSTAMP:20260502T102938
CREATED:20251125T140013Z
LAST-MODIFIED:20260409T150138Z
UID:10000187-1765980000-1765985400@graspcancer.org
SUMMARY:SABCS25 - Group 2A: BEGINNER TRACK: Racial and Health Disparities; Side Effects; Symptom Management
DESCRIPTION:  \nThe 2025 San Antonio Breast Cancer Symposium (SABCS) is a global meeting that highlights clinical\, translational\, and basic breast cancer research. It’s a unique opportunity for advocates to join the conversation. \nThese beginner tracks offer added explanations at a relaxed pace\, ideal for new advocates and anyone who prefers additional clarity. \n\nRegister Below\nThis SABCS25 Poster Walkthrough group will explore key findings from the following posters: \nPoster #PS1-01-06: Patient-reported measures of taxane-induced peripheral neuropathy (TIPN) and risk of dose reductions or worsening quality of life in Black women with breast cancer: analysis from ECOG-ACRIN EAZ171 \nPoster #PS3-01-22: Targeting Disparities: Impact of Mammographic Screening and Social Drivers on Advanced-Stage Triple-Negative Breast Cancer in Vulnerable Populations Across US Counties
URL:https://graspcancer.org/event/sabcs25-group2a/
CATEGORIES:Poster Walkthrough
LOCATION:https://graspcancer.org/event/sabcs25-group2a/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251217T100000
DTEND;TZID=America/New_York:20251217T113000
DTSTAMP:20260502T102938
CREATED:20251125T133013Z
LAST-MODIFIED:20260409T141435Z
UID:10000200-1765965600-1765971000@graspcancer.org
SUMMARY:SABCS25 - 🇧🇷 Group 1G: Câncer de mama de início precoce; Sobrevivência e imagem corporal
DESCRIPTION:  \nSan Antonio Breast Cancer Symposium (SABCS)\, a maior conferência de pesquisa em câncer de mama do mundo\, se torna ainda mais especial com as discussões do GRASP\, que reúne pacientes e cientistas em pequenos grupos para conversar sobre os estudos apresentados na conferência. \nInscreva-se abaixo \nEste grupo do GRASP Poster Walkthrough vai explorar resultados essenciais dos seguintes pôsteres: \nPôster #PS5-05-29: Impacto a longo prazo do câncer de mama de início precoce em mulheres brasileiras \nPôster #PS5-12-27: Impacto da simetrização contralateral imediata na satisfação corporal entre sobreviventes no Brasil \n 
URL:https://graspcancer.org/event/sabcs25-group1g/
CATEGORIES:Poster Walkthrough
LOCATION:https://graspcancer.org/event/sabcs25-group1g/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251217T100000
DTEND;TZID=America/New_York:20251217T113000
DTSTAMP:20260502T102938
CREATED:20251125T132014Z
LAST-MODIFIED:20260409T141803Z
UID:10000197-1765965600-1765971000@graspcancer.org
SUMMARY:SABCS25 - Group 1E: Triple Negative Metastatic Breast Cancer; Antibody-drug Conjugates; Liquid Biopsy
DESCRIPTION:  \nThe 2025 San Antonio Breast Cancer Symposium (SABCS) is a global meeting that highlights clinical\, translational\, and basic breast cancer research. It’s a unique opportunity for advocates to join the conversation. \n\nRegister Below\nThis SABCS25 Poster Walkthrough group will explore key findings from the following posters: \nPoster #PS5-02-29: Clinical data of DB-1305/BNT325 (TROP2 antibody-drug conjugate [ADC]) in patients (pts) with metastatic triple negative breast cancer (mTNBC): Efficacy and safety data from a phase 1/2 trial \nPoster #PS5-07-09: A randomized clinical trial comparing ctDNA-directed therapy change with standard of care in patients with metastatic triple negative breast cancer (mTNBC)
URL:https://graspcancer.org/event/sabcs25-group1e/
CATEGORIES:Poster Walkthrough
LOCATION:https://graspcancer.org/event/sabcs25-group1e/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251217T100000
DTEND;TZID=America/New_York:20251217T113000
DTSTAMP:20260502T102938
CREATED:20251125T131514Z
LAST-MODIFIED:20260409T141815Z
UID:10000196-1765965600-1765971000@graspcancer.org
SUMMARY:SABCS25 - Group 1D: Metastatic Breast Cancer; Liquid Biopsy
DESCRIPTION:  \nThe 2025 San Antonio Breast Cancer Symposium (SABCS) is a global meeting that highlights clinical\, translational\, and basic breast cancer research. It’s a unique opportunity for advocates to join the conversation. \n\nRegister Below\nThis SABCS25 Poster Walkthrough group will explore key findings from the following posters: \nPoster #PS2-07-24: Circulating tumor DNA (ctDNA) biomarker analyses of a phase 1/2 study evaluating vepdegestrant\, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader\, in ER-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (aBC) \nPoster #PS4-03-10: Assessing the impact of real-time serial circulating tumor cell results on the management of patients with metastatic breast cancer
URL:https://graspcancer.org/event/sabcs25-group1d/
CATEGORIES:Poster Walkthrough
LOCATION:https://graspcancer.org/event/sabcs25-group1d/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251217T100000
DTEND;TZID=America/New_York:20251217T113000
DTSTAMP:20260502T102938
CREATED:20251125T131015Z
LAST-MODIFIED:20260409T141328Z
UID:10000195-1765965600-1765971000@graspcancer.org
SUMMARY:SABCS25 - Group 1C: Metastatic Breast Cancer; Brain Metastasis Risk Prediction
DESCRIPTION:  \nThe 2025 San Antonio Breast Cancer Symposium (SABCS) is a global meeting that highlights clinical\, translational\, and basic breast cancer research. It’s a unique opportunity for advocates to join the conversation. \nPrefer a different time? These same posters will be discussed in another session. Click to join Group 2E instead. \n\nRegister Below\nThis SABCS25 Poster Walkthrough group will explore key findings from the following posters: \nPoster #PS5-01-08: Development of the HER2DX Predictor of Brain Metastasis in Advanced HER2-Positive Breast Cancer Treated with First-Line THP \nPoster #PS2-08-05: Multimodal integration of real world genomic and clinical data for the prediction of brain metastasis development in breast cancer \n 
URL:https://graspcancer.org/event/sabcs25-group1c/
CATEGORIES:Poster Walkthrough
LOCATION:https://graspcancer.org/event/sabcs25-group1c/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251217T100000
DTEND;TZID=America/New_York:20251217T113000
DTSTAMP:20260502T102938
CREATED:20251125T130515Z
LAST-MODIFIED:20260409T141352Z
UID:10000194-1765965600-1765971000@graspcancer.org
SUMMARY:SABCS25 - Group 1B: Early Stage HER2+ Breast Cancer; Targeted Therapies
DESCRIPTION:  \nThe 2025 San Antonio Breast Cancer Symposium (SABCS) is a global meeting that highlights clinical\, translational\, and basic breast cancer research. It’s a unique opportunity for advocates to join the conversation. \n\nRegister Below\nThis SABCS25 Poster Walkthrough group will explore key findings from the following posters: \nPoster #PS3-11-28: EmpowHER-208: A phase 2 neoadjuvant study of zanidatamab in combination with chemotherapy in patients with stage II-III HER2-positive early breast cancer \nPoster #PS3-08-27: Repower: a real-world noninterventional study of outcomes and experiences in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) early breast cancer (EBC) treated with an adjuvant cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) plus endocrine therapy (ET)
URL:https://graspcancer.org/event/sabcs25-group1b/
CATEGORIES:Poster Walkthrough
LOCATION:https://graspcancer.org/event/sabcs25-group1b/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Winnipeg:20251209T183000
DTEND;TZID=America/Winnipeg:20251209T203000
DTSTAMP:20260502T102938
CREATED:20251002T155304Z
LAST-MODIFIED:20251209T234807Z
UID:10000168-1765305000-1765312200@graspcancer.org
SUMMARY:GRASP Reception at SABCS25
DESCRIPTION:Attending the 2025 San Antonio Breast Cancer Symposium (SABCS) in person? \nJoin GRASP for our annual reception on Tuesday\, December 9\, from 6:30-8:30pm CT*\, on Terrace Level 3 of the Henry B. Gonzales Convention Center. \nThis tradition at SABCS brings together advocates\, scientists\, and partners to connect and mingle in person outside of formal sessions. \nRefreshments and light fare will be provided. \n*Note: Time listed is Central Standard Time (local in San Antonio time).
URL:https://graspcancer.org/event/sabcs25-reception/
LOCATION:Henry B. Gonzales Convention Center\, 900 E Market St\, San Antonio\, TX\, 78205\, United States
CATEGORIES:Reception
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240827T110000
DTEND;TZID=America/New_York:20240827T120000
DTSTAMP:20260502T102938
CREATED:20251126T133232Z
LAST-MODIFIED:20251126T133232Z
UID:10000091-1724756400-1724760000@graspcancer.org
SUMMARY:Link between Immune Cells and HR+/HER2- Breast Cancer
DESCRIPTION:Dr. Gaia Griguolo will discuss her research and review the poster “Association of tumor-infiltrating lymphocytes (TILs) and immune signatures with PAM50 intrinsic subtyping hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer (BC): A translational analysis of two multicentric neoadjuvant trial” which was presented at the 2024 American Society of Clinical Oncology Annual Meeting (ASCO). This session will explore findings from two neoadjuvant trials\, focusing on how the addition of immunotherapy to chemotherapy can benefit high-risk patients. Join us to review the poster and engage in a discussion on these important findings.\n 
URL:https://graspcancer.org/event/link-between-immune-cells-and-hr-her2-breast-cancer/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240822T100000
DTEND;TZID=America/New_York:20240822T110000
DTSTAMP:20260502T102938
CREATED:20251126T133232Z
LAST-MODIFIED:20251126T133232Z
UID:10000094-1724320800-1724324400@graspcancer.org
SUMMARY:OPERA-01: Palazestrant vs. Standard-of-Care for ER+/HER2- MBC
DESCRIPTION:Elisabeth de Kermadec will discuss the OPERA-01 phase 3 study\, focusing on the efficacy of palazestrant (OP-1250) compared to standard treatments in ER+\, HER2- metastatic breast cancer post endocrine therapy and CDK4/6 inhibitor resistance. We will discuss her study and review the poster “the OPERA-01 phase 3 study with us\, focusing on the efficacy of palazestrant (OP-1250) compared to standard treatments in ER+\, HER2- metastatic breast cancer post endocrine therapy and CDK4/6 inhibitor resistance.” which was presented at the 2024 American Society of Clinical Oncology Annual Meeting (ASCO).\n 
URL:https://graspcancer.org/event/opera-01-palazestrant-vs-standard-of-care-for-er-her2-mbc/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240806T120000
DTEND;TZID=America/New_York:20240806T130000
DTSTAMP:20260502T102938
CREATED:20251126T133232Z
LAST-MODIFIED:20251126T133232Z
UID:10000093-1722945600-1722949200@graspcancer.org
SUMMARY:Plant-Based Diet and Exercise Therapy in HR+ Breast Cancer
DESCRIPTION:Dr. Shoshana Rosenberg will review poster “Effects of plant-based diet (PBD) and exercise therapy (Ex) on weight and body composition in patients with primary hormone receptor (HR) positive breast cancer: A phase 2 randomized controlled trial.” This study explores how a personalized energy-restricted PBD combined with exercise can impact weight and body composition in patients with HR-positive breast cancer\, aiming to improve clinical outcomes by addressing obesity-related risks.\n 
URL:https://graspcancer.org/event/plant-based-diet-and-exercise-therapy-in-hr-breast-cancer/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240801T100000
DTEND;TZID=America/New_York:20240801T110000
DTSTAMP:20260502T102938
CREATED:20251126T133233Z
LAST-MODIFIED:20251126T133233Z
UID:10000092-1722506400-1722510000@graspcancer.org
SUMMARY:Decentralized Biobanking: A New Community Engagement Platform
DESCRIPTION:Dr. Marielle Gross will discuss Decentralized Biobanking\, AKA “de-bi\,” a new community engagement platform for patients to track their donated biosamples\, receive personalized research updates\, and engage with scientists in a privacy-preserving network. We will share details about our first de-bi pilot\, launched in 2023 for a large breast cancer biobank. Next\, we will take you on a live tour of the latest de-bi app\, that breaks new ground in uniting patients\, physicians\, and scientists across the country for ongoing collaboration in ovarian cancer research. Join us to learn about the next-generation technology that will revolutionize community research engagement\, and share your input to help maximize de-bi’s accessibility and inclusiveness for all patients who desire a “digital seat at the table.”\n 
URL:https://graspcancer.org/event/decentralized-biobanking-a-new-community-engagement-platform/
END:VEVENT
END:VCALENDAR